View in EDS HTML Full Text PDF Full Text

Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.

Saved in:
Bibliographic Details
Title: Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Authors: Llombart-Cussac, Antonio1,2,3 (AUTHOR) antoniollombart@medsir.org, Prat, Aleix4,5,6 (AUTHOR), Pérez-García, José Manuel3,7 (AUTHOR), Mateos, José8 (AUTHOR), Pascual, Tomás4 (AUTHOR), Escrivà-de-Romani, Santiago9 (AUTHOR), Stradella, Agostina10 (AUTHOR), Ruiz-Borrego, Manuel11 (AUTHOR), de las Heras, Begoña Bermejo12 (AUTHOR), Keyaerts, Marleen13 (AUTHOR), Galvan, Patricia6 (AUTHOR), Brasó-Maristany, Fara6 (AUTHOR), García-Mosquera, Juan José14 (AUTHOR), Guiot, Thomas15 (AUTHOR), Gion, María16 (AUTHOR), Sampayo-Cordero, Miguel3 (AUTHOR), Di Cosimo, Serena17 (AUTHOR), Pérez-Escuredo, Jhudit3 (AUTHOR), de Frutos, Manuel Atienza18 (AUTHOR), Cortés, Javier2,7,18 (AUTHOR)
Source: European Journal of Nuclear Medicine & Molecular Imaging. Jul2024, Vol. 51 Issue 9, p2733-2743. 11p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:16197070
DOI:10.1007/s00259-024-06683-0